News and Trends

FDA Approves Its First Marijuana-Derived Drug

Epidiolex can reduce the frequency of epileptic seizures.
FDA Approves Its First Marijuana-Derived Drug
Image credit: Getty Images via engadget
2 min read
This story originally appeared on Engadget

In a nationwide first, the US Food and Drug Administration (FDA) has authorized the use of 'Epidiolex', a marijuana derivative which will be used to treat rare forms of epilepsy. Epidiolex -- also known as cannabidiol or CBD -- is a highly-purified version of the many psychoactive compounds found in marijuana and does not result in a high.

GW Pharmaceuticals, the British company responsible for the drug, said currently approved AEDs (anti-epileptic drugs) are not always effective in the majority of patients with Lennox-Gastaut Syndrome (LGS) and Dravet syndrome -- severe forms of childhood-onset epilepsy. However, access to a cannabinoid-medicine like Epidiolex could substantially reduce seizure frequency.

The Drug Enforcement Administration (DEA) classifies marijuana or cannabis as a Schedule 1 substance -- which means there is "no currently accepted medical use and a high potential for abuse." Accordingly, before Epidiolex is ready for use amongst patients, it needs to be appropriately reclassified -- something GW Pharmaceuticals expects to see happen within the next three months.

The FDA gave Epidiolex the green light following a number of controlled clinical trials. It's not the first time marijuana's health benefits have been recognized -- a wide-scale study from the National Academies of Science, Engineering and Medicine previously pointed out the link between cannabinoids and pain relief. Despite the positive impact such efforts afford, strides in medical research haven't led to nationwide marijuana legalization.

The FDA was careful to mention its approval of cannabidiol -- one of over 100 compounds found within marijuana -- does not reflect an endorsement for all of marijuana's components. In fact, the FDA warns against 'impostor' CBD-containing products like oil drops, capsules and creams which are sometimes sold with false medical promises of curing life-threatening diseases such as cancer. Pending the required rescheduling, Epidiolex should be available to patients by the fall.

By Javier Hasse
From retailers to growers, producers, and suppliers, there’s a seemingly never-ending list of startup opportunities in this emerging market. In Start Your Own Cannabis Business, marijuana, biotech, and entrepreneurship reporter Javier Hasse introduces forward-thinking entrepreneurs like you to the industry and shares hard-earned tips and success stories from pioneers and visionaries in the marijuana industry.
Learn More

Latest on Green Entrepreneur

My Queue

There are no Videos in your queue.

Click on the Add to Queue next to any video to save to your queue.

There are no Articles in your queue.

Click on the Add to Queue next to any article to save to your queue.

Podcasts episodes coming soon for GreenEntrepreneur.com

There are no Podcasts in your queue.

Click on the Add to Queue next to any podcast episode on Entrepreneur.com to save to your queue.

You're not following any authors.

Click the Follow button on any author page to keep up with the latest content from your favorite authors.

Education and Employment Is High in Cannabis-Friendly States

Entrepreneur Media, Inc. values your privacy. In order to understand how people use our site generally, and to create more valuable experiences for you, we may collect data about your use of this site (both directly and through our partners). The table below describes in more detail the data being collected. By giving your consent below, you are agreeing to the use of that data. For more information on our data policies, please visit our Cookie Policy.

Name Category
Google Ad Serving, Ad Targeting, Analytics/Measurement, Optimisation
Rubicon Ad Serving
Teads Ad Serving
Nativo Ad Serving
Teads Ad Serving
New Relic Analytics/Measurement
Log Entries Analytics/Measurement
Sailthru Content Customization